BeStock  
Stocks › SBHMY

SINO BIOPHARMACEUT SBHMY

US equityMarket cap rank #1132
$14.40 +$0.00 (0.00%)
Market closed · Nov 22, 2:00 pm ET
Open$14.23
Prev close$14.40
Day range$14.23 – $14.40
Volume200
Market cap$14.50B
P/E (TTM)37.9
Dividend yield2.13%

SBHMY Stock News

Headlines matching SINO BIOPHARMACEUT or the SBHMY ticker, most recent first.

  • Sino Biopharm (1177.HK): Significant Improvement in Profitability; Breakthrough in Out-licensing of Innovative Drugs PositiveShouchuang Securities · 7 Sep 2026 · Related
  • Sino Biopharm (01177.HK): Platform-based innovation combined with global expansion drives the realization of big pharma status, ushering in a second growth curve PositiveGuosheng Securities · 3 Sep 2026 · Related
  • Hong Kong Stocks in Motion | Sino Biopharm (01177) rises nearly 4%; subsidiary reaches strategic cooperation with STADA on biosimilars, securing an upfront payment of up to €53 million PositiveZhitong Finance · 29 Sep 2026 · Related
  • Sino Biopharm (1177.HK): Profitability significantly improved; innovation transformation and global partnerships continue to deliver resultsWestern Securities · 23 Sep 2026 · Related
  • Sino Biopharm (01177 HK): Innovative drug business grows rapidly; BD efforts are accelerating realization.Zheshang Securities · 29 Aug 2026 · Related
  • Sino Biopharm (01177.HK) 2026 Interim Report Commentary: Dual-Drive from Innovative Products and BD, with AI Empowering the Entire Business ChainHuachuang Securities · 28 Aug 2026 · Related
  • Sino Biopharm (1177.HK): AI Deeply Empowers the R&D System; Two-Way BD Accelerates GlobalizationNortheast Securities · 27 Aug 2026 · Related
  • Sino Biopharm (01177.HK): BD deal successfully closed, with the innovative pipeline accelerating its realization.Shenwan Hongyuan Research · 26 Aug 2026 · Related
  • Sino Biopharm (1177.HK): Profit Quality Significantly Improved; Innovative Pipeline Accelerating Realization PositiveChina Securities Co., Ltd. · 23 Aug 2026 · Related
  • Major Bank Ratings | Daiwa: Raises Sino Biopharm’s Target Price to HK$7.2, Reiterates "Buy" Rating PositiveGelonghui Finance · 21 Aug 2026 · Related
  • Sino Biopharm (1177.HK): BD Deals Are Being Realized, and the Platform's Innovative Value Has Been ValidatedCMB International · 21 Aug 2026 · Related
  • SINO BIOPHARM: COMPLETION OF SHARE TRANSACTION - ACQUISITION OF 100% EQUITY INTEREST IN HYGIEIA INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER GENERAL MANDATEHKEX · 30 Mar 2026 · Related
  • SINO BIOPHARM: NEXT DAY DISCLOSURE RETURNHKEX · 30 Mar 2026 · Related
  • SINO BIOPHARM: NEXT DAY DISCLOSURE RETURNHKEX · 27 Mar 2026 · Related
  • SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEMEHKEX · 27 Mar 2026 · Related

Discussion

No comments yet — be the first to weigh in on SBHMY.

Sign in to join the discussion.

Scroll to Top